Contract manufacturing arm of Biocon, Syngene International Limited, reported a profit after tax of ₹131 crore for the quarter ended December 31, compared to ₹112 crore in Q3FY24.
The company recorded growth across all business divisions, with notable performance in Research Services and the Contract Development and Manufacturing Organization (CDMO) segment, driven by increased traction in biologics.
The revenue from operations was up by 11 per cent y-o-y to ₹944 crores, and increased sequentially by 6 per cent from the last year’s quarter.
Commenting on the quarter, Jonathan Hunt, Managing Director and Chief Executive Officer of Syngene International Limited, said, “The third quarter sets us up well for the next quarter, with the Discovery Services division witnessing initial ‘China+1’ pilot projects, involving large and mid-sized pharma companies, starting to convert into longer-term contracts.”
He added that the company’s focus is on further business development and building the sales pipeline.
For the nine-month period ended December 31 (9MFY25), Syngene reported revenue of ₹2,624 crore, up 2 per cent from ₹2,572 crore in 9MFY24.
The shares of the company closed at ₹847.25, up by 2.44 per cent on the BSE.